Opioid kappa receptor agonists - Pipeline Insight, 2024

Opioid kappa receptor agonists - Pipeline Insight, 2024

DelveInsight’s, “Opioid Kappa Receptor Agonists - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Opioid Kappa Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Opioid Kappa Receptor Agonists Understanding

Opioid Kappa Receptor Agonists: Overview

Opioids have been used for thousands of years for the treatment of pain. Opioid analgesics can act through three different types of opioid receptors, called mu, delta, and kappa. To prevent undesirable CNS and opioid receptor mediated side effects, there has been an effort to develop opioids which activate peripheral kappa opioid receptors present on sensory nerves, immune cells and the dorsal root ganglion (DRG). Such compounds, Kappa Opioid Receptor Agonists (KORAs), are thought to have the potential to provide pain relief (peripheral opioid analgesia) without producing significant CNS and mu-opioid mediated side effects.

Function – Both classical opioid receptors (MOP/ KOP/DOP) and the non-classical NOP opioid receptor couple to inhibitory G-proteins. Activation of opioid receptors, for example MOP with morphine leads to: (i) closing of voltage sensitive calcium channels (VSCC); (ii) stimulation of potassium efflux leading to hyperpolarization; and (iii) reduced cyclic adenosine monophosphate (cAMP) production via inhibition of adenylyl cyclase. Overall, this results in reduced neuronal cell excitability leading to a reduction in transmission of nerve impulses along with inhibition of neurotransmitter release.

Opioid Kappa Receptor Agonists- Kappa opioid receptor (KOPr) agonists have recently received increased attention due to their analgesic effects and lack of abuse potential. There are several strategies currently used to develop safer and more effective KOPr agonists. These strategies include identifying G-protein biased agonists; developing peripherally-restricted KOPr agonists without centrally-mediated side-effects; and developing mixed opioid agonists, which target multiple receptors at specific ratios to balance side-effect profiles and reduce tolerance.

Opioid Kappa Receptor Agonists Emerging Drugs Chapters

This segment of the Opioid Kappa Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Opioid Kappa Receptor Agonists Emerging Drugs

• Nalfurafine hydrochloride: Shenyang Sunshine Pharmaceutical

Nalfurafine hydrochloride (TRK-820 hydrochloride) is a potent selective and orally active G protein-biased kappa opioid receptor (KOR)-agonist with high translational potential. Nalfurafine hydrochloride (TRK-820 hydrochloride) enhances the therapeutic potential of MOR-targeting analgesics, has the potential for uremic pruritis treatment. Shenyang Sunshine Pharmaceutical has initiated a phase III clinical trial for the treatment of Uremic Pruritus.

• Asimadoline: Tioga Pharmaceuticals

Asimadoline is an orally active, highly selective kappa-opioid receptor agonist with approximately 500-fold greater affinity for human kappa-, as compared with either delta- or mu-opioid receptors. Due to its high selectivity for the kappa-opioid receptor, asimadoline does not produce mu-opioid like side-effects. Due to its mechanism of action, asimadoline has the potential to treat pruritus associated with a variety of conditions, including atopic dermatitis, psoriasis, end-stage renal disease, liver diseases such as cholestatic disease and primary biliary cirrhosis, malignancies, adverse drug effects, and certain orphan diseases. The drug is currently in Phase II stage of development for the treatment of pruitis.

Further product details are provided in the report……..

Opioid Kappa Receptor Agonists: Therapeutic Assessment

This segment of the report provides insights about the different Opioid Kappa Receptor Agonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Opioid Kappa Receptor Agonists

There are approx. 10+ key companies which are developing the Opioid Kappa Receptor Agonists. The companies which have their Opioid Kappa Receptor Agonists drug candidates in the most advanced stage, i.e. Phase III include Shenyang Sunshine Pharmaceutical.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III )
• Mid-stage products (Phase II )
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Opioid Kappa Receptor Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intravenous
• Intramuscular
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Opioid Kappa Receptor Agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid Kappa Receptor Agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Kappa Receptor Agonists drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Kappa Receptor Agonists R&D.
• The therapies under development are focused on novel approaches for Opioid Kappa Receptor Agonists.

Opioid Kappa Receptor Agonists Report Insights

• Opioid Kappa Receptor Agonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Opioid Kappa Receptor Agonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Opioid Kappa Receptor Agonists drugs?
• How many Opioid Kappa Receptor Agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Opioid Kappa Receptor Agonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Opioid Kappa Receptor Agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Opioid Kappa Receptor Agonists and their status?
• What are the key designations that have been granted to the emerging drugs?